PFE Stock Analysis & IQ Rating | Pfizer

 Earnings are forecast to grow

 Trading below its fair value

 Upgraded on attractively valued

 Investors confidence is positive

Heres What Analysts Think About Pfizer Inc. (PFE). Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price target of $30.00. The same day Bernstein analyst Courtney Breen reiterated a Hold rating on the stock keeping the associated price target the [….]

Today

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It. Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore it is wise to be aware of the facts that can impact the stocks prospects.

Fri Dec 26, 2025

Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study. ) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with .In October 2024 the Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) or hemophilia B (congenital factor IX deficiency).European Hemophilia Consortium (EHC) a non-profi

Tue Dec 23, 2025

Flagship Pioneering and Repertoire® Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer. Repertoire and Pioneering Medicines Flagships in-house drug development unit will jointly conduct research activities leveraging Repertoires DECODE™ platform CAMBRIDGE Mass. Dec. 22 2025 /PRNewswire/ -- Flagship Pioneering a scientific innovation engine for transformative...

Mon Dec 22, 2025

Pfizer: Downgrade To Hold On Lower 2026 Revenue Guidance And Potential Growth Tracks.

Mon Dec 22, 2025

Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock. Pfizer shares fall after a muted 2026 outlook with projected modest revenue growth lower COVID sales and deal dilution weighing on investor sentiment.

Fri Dec 19, 2025

Pfizer Plays Catchup In Obesity Market Licenses Weight-loss Drug From Fosun. Playing catch-up in the anti-obesity business Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal

Thu Dec 18, 2025

Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation. Fintel reports that on December 17 2025 Morgan Stanley maintained coverage of Pfizer (NYSE:PFE) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 18.46% Upside

Thu Dec 18, 2025

Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer . (RTTNews) - Astellas Pharma Inc. and Pfizer Inc. announced positive topline results from the Phase 3 EV-304 clinical trial (KEYNOTE-B15) evaluating PADCEV (enfortumab vedotin) a Nectin-4 directed antibody-drug conjugate in combination with Keytruda®. (pembrolizumab) a PD-1 inh

Thu Dec 18, 2025

Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress. We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Pfizer Inc tops our list for being one of the most undervalued pharmaceutical stocks. On Friday December 12 2025 The Fly reported that Morgan Stanley maintained its Hold (Equal‑Weight) rating on PFE. while lowering the price target to $28 from [….]

Wed Dec 17, 2025